191 related articles for article (PubMed ID: 37729017)
1. CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells.
Werner AN; Kumar AI; Charest PG
Mol Biol Cell; 2023 Dec; 34(13):ar128. PubMed ID: 37729017
[TBL] [Abstract][Full Text] [Related]
2. Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion.
Collins SE; Wiegand ME; Werner AN; Brown IN; Mundo MI; Swango DJ; Mouneimne G; Charest PG
Mol Biol Cell; 2023 Feb; 34(2):ar9. PubMed ID: 36542482
[TBL] [Abstract][Full Text] [Related]
3. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
4. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
5. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
6. K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L/CUX1 pathway.
Wang L; Zhao Y; Xiong Y; Wang W; Fei Y; Tan C; Liang Z
Exp Cell Res; 2018 Jan; 362(2):424-435. PubMed ID: 29246726
[TBL] [Abstract][Full Text] [Related]
7. RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.
Castel P; Dharmaiah S; Sale MJ; Messing S; Rizzuto G; Cuevas-Navarro A; Cheng A; Trnka MJ; Urisman A; Esposito D; Simanshu DK; McCormick F
Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34380736
[TBL] [Abstract][Full Text] [Related]
8. Ras, PI3K and mTORC2 - three's a crowd?
Smith SF; Collins SE; Charest PG
J Cell Sci; 2020 Oct; 133(19):. PubMed ID: 33033115
[TBL] [Abstract][Full Text] [Related]
9. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
10. Direct physical interaction of active Ras with mSIN1 regulates mTORC2 signaling.
Lone MU; Miyan J; Asif M; Malik SA; Dubey P; Singh V; Singh K; Mitra K; Pandey D; Haq W; Amita H; Singh PK; Kiess W; Kaessner F; Garten A; Bhadauria S
BMC Cancer; 2019 Dec; 19(1):1236. PubMed ID: 31856761
[TBL] [Abstract][Full Text] [Related]
11. The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.
Kovalski JR; Bhaduri A; Zehnder AM; Neela PH; Che Y; Wozniak GG; Khavari PA
Mol Cell; 2019 Feb; 73(4):830-844.e12. PubMed ID: 30639242
[TBL] [Abstract][Full Text] [Related]
12. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A; Chavez V; Strasberg-Rieber M; Rieber M
BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
[TBL] [Abstract][Full Text] [Related]
14. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
15. Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
Tsukumo Y; Naito M; Suzuki T
PLoS One; 2020; 15(3):e0229712. PubMed ID: 32130260
[TBL] [Abstract][Full Text] [Related]
16. SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.
Ruiz CF; Montal ED; Haley JA; Bott AJ; Haley JD
FASEB J; 2020 Aug; 34(8):10574-10589. PubMed ID: 32568455
[TBL] [Abstract][Full Text] [Related]
17. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.
Bellier J; Nokin MJ; Caprasse M; Tiamiou A; Blomme A; Scheijen JL; Koopmansch B; MacKay GM; Chiavarina B; Costanza B; Rademaker G; Durieux F; Agirman F; Maloujahmoum N; Cusumano PG; Lovinfosse P; Leung HY; Lambert F; Bours V; Schalkwijk CG; Hustinx R; Peulen O; Castronovo V; Bellahcène A
Cell Rep; 2020 Feb; 30(5):1400-1416.e6. PubMed ID: 32023458
[TBL] [Abstract][Full Text] [Related]
18. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A; McSharry M; Berger AH
BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
